Payment overview · 2025
General Payments
$48.85
3 reported records · 1 companies
Healthcare provider profile · identity verified
Donald E Odens, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LE MARS, IA · NPI 1801150396
Verified facts
What the public records show
CMS Open Payments records show Donald E Odens, M.D. received $48.85 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.85 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.85 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.85 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 297 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 59 |
| Omeprazole | Omeprazole | 344 | 39 |
| Lisinopril | Lisinopril | 322 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 50 |
| Eliquis | Apixaban | 297 | 31 |
| Furosemide | Furosemide | 217 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 30 |
| Metformin Hcl | Metformin Hcl | 198 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 32 |
| Sertraline Hcl | Sertraline Hcl | 153 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 152 | 22 |
| Gabapentin | Gabapentin | 146 | 22 |
| Losartan Potassium | Losartan Potassium | 133 | 21 |
| Allopurinol | Allopurinol | 128 | 16 |
| Mounjaro | Tirzepatide | 128 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 25 |
| Potassium Chloride | Potassium Chloride | 122 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 29 |
| Simvastatin | Simvastatin | 120 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 13 |
| Famotidine | Famotidine | 97 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 93 | 19 |
| Carvedilol | Carvedilol | 85 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 82 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 79 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 59 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 59 | 12 |
| Mirtazapine | Mirtazapine | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Prednisone | Prednisone | 54 | 29 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Finasteride | Finasteride | 47 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 29 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 33 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Veozah | Fezolinetant | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Etodolac | Etodolac | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.85 · 3 records | PFIZER INC. | ELIQUIS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error